Insider transaction and option exercises
Joana Goncalves, Chief Medical Officer at Oruka Therapeutics, Inc. (NASDAQ:ORKA), completed the sale of 7,000 shares of the company's common stock on April 15, 2026, generating roughly $462,829 in proceeds. The disposals were carried out across multiple trades, with sale prices spanning $65.7291 to $67.384 per share. On the same date she also exercised rights to acquire 7,000 shares - 3,500 through employee stock options at an exercise price of $6.84 and 3,500 through employee warrants at an exercise price of $7.80 - for a combined cost of $51,240.
Context around the stock price and trading signals
The sales occurred while ORKA was trading near a 52-week high of $67.94, after the share price rose about 666% over the past year. InvestingPro analysis cited in connection with the trades flags the stock as appearing overvalued relative to its Fair Value estimate and places ORKA among the more overvalued names covered on the platform. An InvestingPro technical tip additionally noted the stock is trading in overbought territory based on RSI indicators; the platform referenced 15 additional exclusive tips available to its subscribers.
Planned trading program
The disposition of shares was implemented under a Rule 10b5-1 trading plan that Goncalves had established on September 19, 2025. The use of an approved trading plan is noted in the disclosures accompanying the transactions.
Analyst activity and clinical program expectations
Analysts have recently adjusted their outlooks for Oruka Therapeutics amid developments linked to the ORKA-001 program and the EVERLAST-A clinical trial.
- H.C. Wainwright reiterated a Buy rating and increased its price target from $40 to $70, raising its probability of approval for ORKA-001 to 50% in anticipation of positive EVERLAST-A data.
- BTIG raised its price target to $78, citing higher peak sales estimates for ORKA-001 in psoriasis because of recent market growth in the IL-23 class. BTIG also moved the timing for EVERLAST-A Phase 2a 16-week induction data up to the second quarter of 2026, attributing the change to rapid enrollment.
- Stifel maintained a Buy rating with a $72 price target and said it expects upcoming data from the EVERLAST-A study to provide the first patient data for a next-generation IL-23p19 antibody.
- Guggenheim significantly raised its price target to $125, increasing its probability of success estimate for the ORKA-001 program to 75% and anticipating topline results from the EVERLAST-A study - which involves 84 patients - to be reported in May.
What this combination of activity signals
The transactions combine an executive sale executed through an established 10b5-1 plan with concurrent option and warrant exercises. At the same time, a set of bullish analyst moves — higher price targets and raised probabilities of success for ORKA-001 — point to increased market expectations tied to forthcoming trial results for the EVERLAST-A program. InvestingPro's valuation and technical notes provide a counterpoint, highlighting overvaluation versus Fair Value and overbought technical readings.
Limitations and remaining questions
Details in the public filings and the analyst notes outline the mechanics of the trades, the exercise prices, the trading plan date, and the specific analyst actions and estimates. The information available does not provide additional motive or timing rationale beyond the established 10b5-1 plan, nor does it include further commentary from the company or the insider beyond the recorded transactions and analyst commentary cited above.